Goldman Sachs Group Inc.’s alternative investment division has reached an agreement to acquire a majority stake in Dutch generic drugmaker Synthon from BC Partners. BC Partners will retain a minority interest in Synthon to aid in its future growth, as confirmed in a statement released on Monday.

The financial specifics of the deal were not disclosed, but earlier reports from Bloomberg indicated that Goldman Sachs outbid other potential buyers, valuing Synthon at approximately €2 billion ($2.1 billion).

Established in 1991, Synthon International specializes in the development and manufacturing of generic drugs across various therapeutic areas, including oncology and central nervous system disorders.